Virchow Laboratories Group – Who we are Prof. Yan Hongli

Prof. Yan Hongli

Curriculum Vitae

Hongli Yan, Professor, Ph.D, MD, doctoral supervisor,
Proficient at molecular pathology and laboratory diagnosis, especially in the area of companion Diagnostics for tumor target therapy, immunotherapy, and molecular diagnosis for genetic disorders. In recently five years, I have obtained some grants, such as presided over the national "863" project (2 million), the national "973" corpus (2006-2016), the national natural science foundation of China (6), key basic research project of Shanghai, Shanghai science and technology research projects and other projects, as well as the Shanghai pujiang talent, the Shanghai outstanding young teacher talent fund, the national outstanding youth fund virus lab, changhai hospital, all the young funds, personnel issues such asAs the second or the third major academic backbone, he participated in the national "973", "863", and key projects of the national natural science foundation.
Has published more than 50 papers, some papers were published in Hepatology (14.055), EMBO J (10.748), Oncogene (2 papers, 8.558), Cancer letter (5.618), Clin Chem (7.921) and other journals. The article published in EMBO J in 2009 has been cited more than 300 times. Articles published in Cancer Sci magazine were recommended by the Japanese Cancer society, awarded the 2009 young scientist award (only 3 winners per year), and invited to present at the 68th annual academic conference of the Japanese Cancer society.
Published five books as chief editor or deputy editor. As editor of world Chinese digestive magazine (2008-present) and Open Journal of Animal Sciences (2011-present), reviewer of Clinical Genetics, Viral immunology, Plos one, Cell death & Disease, etc.The responsible editor (section editor) of Translational Cancer Research(TCR) magazine (SCIE) was invited to present the conference or special report at the 2nd international conference on Hepatology (2016, Chicago), the 5th world gene therapy conference (Atlanta, USA, 2015) and the 8th world Cancer conference (dalian, China, 2015).As the main accomplice, he won the second prize of Shanghai natural science award, the second prize of Shanghai medical science and technology award, the third prize of China medical science and technology award, the second prize of fujian province science and technology progress, the science and technology award of Chinese medicine society, the second prize of military science and technology progress and other awards.

颜宏利简历

男,1974年7月出生于山东曲阜,博士，教授，博士生导师, 长海医院生殖中心执行主任,实验诊断科副主任

近年来主要紧紧围绕肿瘤与遗传病的早期诊断与发病机制开展研究，曾主持国家“863”课题（200万）、国家"973"子课题(2006-2016, 获滚动资助)、国家自然科学基金（6项）、上海市重点基础研究项目、上海市科技攻关项目等项目，以及上海市浦江人才、上海市优秀青年教师人才基金、国家病毒实验室优秀青年基金、长海医院杰青苗子基金等人才课题，并先后作为第2或第3主要学术骨干参与了国家“973”、“863”、国家自然科学基金重点项目等课题。

共发表论文50余篇，SCI论文42篇，总引用率545次. 第1作者或通讯作者SCI论文24篇. 所发表论文影响因子大于5的论文有15篇, 分别发表在Hepatology (14.055)、EMBO J (10.748)、Oncogene (2篇, 8.558)、Cancer letter (5.618)、Clin Chem （7.921）等杂志。2009年发表在EMBO J的文章迄今被国外SCI杂志引用190余次。发表在Cancer Sci杂志的文章被日本癌症协会推荐，授予“2009年青年科学家奖” (每年仅有3人获奖)，并被邀请在 “日本癌症学会第68届学术年会”做大会报告。其他研究论文曾获“夏家辉杰出青年基金会议资助计划”、“刘新垣院士学术交流奖”，全国医药生物工程学术研讨会优秀论文一等奖、上海市第九届青年科技论文奖等。

作为主编（主译）或副主编出版专著5部。任《世界华人消化杂志》（2008年－今）和《Open Journal of Animal Sciences》（2011－今）编委，为Clinical Genetics，Viral immunology、Plos one、Cell death & Disease等杂志审稿人， Translational Cancer Research(TCR)杂志(SCIE收录)责任编辑（section editor），应邀在第二届国际肝癌会议（2nd international conference on Hepatology，2016，芝加哥）、第五届世界基因治疗大会（Atlanta，USA，2015），第八届世界癌症大会(大连，中国，2015)做大会或专题报告。作为主要完成人获上海市自然科学二等奖、上海市医学科技奖二等奖、中华医学科技奖三等奖、福建省科技进步二等奖、中华中医学会科技奖、军队科技进步二等奖等多项奖项。

承担课题:

1．国家自然科学基金：早发肝癌高频整合位点HBx-SINE的垂直传递及其促进肝癌发生的分子机制81872225，直接费用：64万元，项目起止年月： 2019年01月至 2022年12月

2 国家自然科学基金：低氧诱导的hsa-circ_0085549靶向调控PVT1促进结直肠癌侵袭转移的作用与机制研究（81672350），80.00万元，项目起止年月：2017年01月至 2020年12月

3．国家自然科学基金：EGFR靶向抑制剂耐药新机制：GRHL2介导上皮-间质转化和抑制EGFR再循环（81472770），72.00万元，项目起止年月：2015年01月至 2018年12月

4. 国家自然科学基金：DNA 甲基化介导的miR-106a-363 表达激活及其促结直肠癌发生的作用与机制研究(81272280)，2013－2016，75万，负责人。

5. 国家“863”导向课题：新型靶向溶栓药AnxB1ScuPA的研制与临床前研究（2009AA02Z113），2009－2012，200万，负责人

6．国家自然科学基金：细胞增殖抑制基因HSG/MFN2在MSI结直肠癌发生、发展的作用及机制（30801328），2009-2012, 20万，负责人。

7. 国家自然科学基金：核酸疫苗pcDNA3-ganxB1诱导猪囊尾蚴细胞凋亡的机理研究（30271167），2003－2005，18万，负责人。

8. 上海市重点基础研究项目：遗传性非息肉病性结直肠癌分子标记物的筛选及功能研究（05JC14043），30万，负责人。

9. 上海市自然科学基金：HSG/MFN2下调在MSI肿瘤发生中的意义及其机制（08ZR1404000），10万，负责人。

10.国家“新药创制”重大科技专项：靶向溶栓药mAnxB1ScuPA的临床前研究（2009ZX09102-238），300万，2009－2012，第2。

11. 上海市科委重点科技攻关项目：新型溶栓药的临床前研究，2007－2010，100万，第2.

12. 国家科技支撑计划课题（子课题）：重大遗传病产前筛查、诊断综合技术体系研究（2006BAI05A05），2006－2008，第2.

13. 国家“973”课题：高原低氧等环境因素损伤适应机理及干预措施，2006－2011，2011-2006滚动资助, 子课题负责人.

荣誉获奖：

博士论文获全国百篇博士论文提名奖和上海市优秀研究生成果。2009年被评为“上海市优秀青年教师”，2012年获上海市“浦江人才”；2013年获第二军医大学“东方学者特聘教授”提名；连续入选学校“5511”优秀青年人才库，被评为第二军医大学“学习成才标兵”，并获得军队优秀专业技术干部津贴，2009年全校基础组答辩第1名晋升教授（是学校最年轻的教授之一）。2013年作为人才引进至长海医院实验诊断科从事肿瘤个体化治疗和分子诊断工作, 2014年作为长海医院获得杰青苗子基金资助。

1、2004年，全国百篇博士论文提名奖

2、2005年，上海市优秀博士论文

3、2009年，青年科学家奖（Young Scientist Award），日本癌症协会

4、2003年，上海市优秀青年教师后备人选

5、2005年，第二军医大学“学习成才标兵”

6、2006年，个人三等功，军队优秀专业技术干部津贴

7、2009年，上海市优秀青年教师

8、2012年，上海市浦江人才

9. 2013年，东方学者特聘教授提名奖

10. 2014年，长海医院杰青苗子

人才基金:

1. 上海市重点弱势学科支持项目-检验病理学科(2015ZB0202), 2015.8-2018.8, 150万, 检验学科负责人.

2. 上海市浦江人才基金, 肝癌靶向治疗药物mAnxB1-MLT的研制，2012.8-2014.8, 20万

3. 第二军医大学"5511"人才培养计划暨长海医院杰青苗子培育计划, 2015.1-2017.12, 60万

4. 国家病毒学重点实验室人才合作计划, 2015.1-2016.12, 6万元.

5. 上海市优秀青年教师后备人选基金：抗凝、溶栓双功能导向溶栓剂mA5UKB的研制，6万，2004－2006。

主要发表论文：第一或通讯

1. Cao Y, Chen M, Tang D, Yan H, Ding X, Zhou F, Zhang M, Xu G, Zhang W, Zhang S,Zhuge Y, Wang L, Zou X. The proton pump inhibitor pantoprazole disrupts proteindegradation systems and sensitizes cancer cells to death under various stresses. Cell Death Dis. 2018 May 22;9(6):604. doi: 10.1038/s41419-018-0642-6.

2. Duan G, Shi M, Xie L, Xu M, Wang Y, Yan H, Zhuge Y, Zou X. Increased Glutamine Consumption in Cisplatin-Resistant Cells Has a Negative Impact on Cell Growth.Sci Rep. 2018 Mar 6;8(1):4067. doi: 10.1038/s41598-018-21831-x.

3. Zhang B, Deng C, Wang L, Zhou F, Zhang S, Kang W, Zhan P, Chen J, Shen S, Guo H, Zhang M, Wang Y, Zhang F, Zhang W, Xiao J, Kong B, Friess H, Zhuge Y, Yan H,Zou X. Upregulation of UBE2Q1 via gene copy number gain in hepatocellular carcinoma promotes cancer progression through β-catenin-EGFR-PI3K-Akt-mTOR signaling pathway. Mol Carcinog. 2018 Feb;57(2):201-215. doi: 10.1002/mc.22747.

4. Ma L, Yan H, Zhao H, Sun J. Grainyhead-like 2 in development and cancer. Tumour Biol. 2017 May;39(5):1010428317698375.

5. Xiao L, Ding G, Ding Y, Deng C, Ze X, Chen L, Zhang Y, Song L, Yan H, Liu F,Ben X. Effect of probiotics on digestibility and immunity in infants: A study protocol for a randomized controlled trial. Medicine (Baltimore). 2017 Apr;96(14):e5953. doi: 10.1097/MD.0000000000005953. PubMed PMID: 28383398; PubMed Central PMCID: PMC5411182.

6. Duan G, Tang Q, Yan H, Xie L, Wang Y, Zheng XE, Zhuge Y, Shen S, Zhang B,Zhang X, Wang J, Wang W, Zou X. A Strategy to Delay the Development of Cisplatin Resistance by Maintaining a Certain Amount of Cisplatin-Sensitive Cells. Sci Rep.2017 Mar 27;7(1):432. doi: 10.1038/s41598-017-00422-2.

7. Zhang B, Shi X, Xu G, Kang W, Zhang W, Zhang S, Cao Y, Qian L, Zhan P, Yan H, To KF, Wang L, Zou X. Elevated PRC1 in gastric carcinoma exerts oncogenic function and is targeted by piperlongumine in a p53-dependent manner. J Cell Mol Med. 2017 Jul;21(7):1329-1341. doi: 10.1111/jcmm.13063. Epub 2017 Feb 12.

8. Song L, Qu D, Zhang Q, Jiang J, Zhou H, Jiang R, Li Y, Zhang Y, Yan H. Phytosterol esters attenuate hepatic steatosis in rats with non-alcoholic fatty liver disease rats fed a high-fat diet. Sci Rep. 2017 Feb 7;7:41604. doi: 10.1038/srep41604. Erratum in: Sci Rep. 2017 Aug 24;7:46884.

9. Li BB, Li DL, Chen C, Liu BH, Xia CY, Wu HJ, Wu CQ, Ji GQ, Liu S, Ni W, Yao DK, Zeng ZY, Chen DG, Qin BD, Xin X, Yan GL, Dan Tang, Liu HM, He J, Yan H, Zhu WJ, Yu HY, Zhu L. Potentials of the elevated circulating miR-185 level as a biomarker for early diagnosis of HBV-related liver fibrosis. Sci Rep. 2016 Sep 28;6:34157. doi: 10.1038/srep34157.

10. Wang ZG, Zheng H, Gao W, Han J, Cao JZ, Yang Y, Li S, Gao R, Liu H, Pan ZY, Fu SY, Gu FM, Xing H, Ni JS, Yan HL, Ren H, Zhou WP. eIF5B increases ASAP1 expression to promote HCC proliferation and invasion. Oncotarget. 2016 Sep 20;7(38):62327-62339

11. Song L, Du A, Xiong Y, Jiang J, Zhang Y, Tian Z, Yan H*. γ-Aminobutyric acid inhibits the proliferation and increases oxaliplatin sensitivity in human colon cancer cells. Tumour Biol. 2016 Sep 19. [Epub ahead of print] PubMed PMID:27644246（通讯作者）

12. anmei Deng，yonggang hong，liqiang hao，xiaobo sun，kang wu，chaoping fang，mingli Gu，hongli yan*，Determination of CpG Island Methylator Phenotype (CIMP) status of colon cancer in plasma using Droplet digital PCR, Clinical chemistry, 2016, (in press). （通讯作者, IF7.911）

13. Yan H, Yang Y, Zhang L, Tang G, Wang Y, Xue G, Zhou W, Sun S. Characterization of the genotype and integration patterns of hepatitis B virus in early- and late-onset hepatocellular carcinoma. Hepatology. 2015 Jun;61(6):1821-31 （第一作者和通讯作者）（IF 11.055）

14. Hong-li Yan, Geng Xue, Qian Mei, Shu-han Sun, et al., Repression of the miR-17-92 cluster by p53 has an important function in hypoxia-induced apoptosis. EMBO J 2009; 28:2719-32. （第一作者）（IF10.434）

15. Song L, Ma L, Cong F, Shen X, Jing P, Ying X, Zhou H, Jiang J, Fu Y, Yan H. Radioprotective effects of genistein on HL-7702 cells via the inhibition of apoptosis and DNA damage. Cancer Lett. 2015; 366(1):100-11. （通讯作者）（IF5.469）

16. Yan H, Tang G, Wang H, Hao L, He T, Sun X, Ting AH, Deng A, Sun S. DNA methylation reactivates GAD1 expression in cancer by preventing CTCF-mediated polycomb repressive complex 2 recruitment. Oncogene. 2016 Jul 28;35(30):4020. doi: 10.1038/onc.2016.28.（IF8.559）（第一和通讯作者）

17. Xue G，Yan HL，Zhang Y，Hao LQ，Zhu XT，Mei Q，Sun SH. (*) c-Myc-mediated repression of miR-15-16 in hypoxia is induced by increased HIF-2α and promotes tumor angiogenesis and metastasis by upregulating FGF2. Oncogene，2015 Mar 12;34(11):1393-406. (IF 8.559) （*Co-first author）

18. Wang C, Chang JF, Yan H, Wang DL, Liu Y, Jing Y, Zhang M, Men YL, Lu D, Yang XM, Chen S, Sun FL. A conserved RAD6-MDM2 ubiquitin ligase machinery targets histone chaperone ASF1A in tumorigenesis. Oncotarget. 2015 Aug 22.[Epub ahead of print] (共同第一作者）(IF6.359）

19. Chen S, Yan H, Zhang L, Kong W, Sun Y, Zhang W, Chen Y, Deng A. Cryptococcus Neoformans Infection and Immune Cell Regulation in Human Monocytes. Cell Physiol Biochem. 2015;37:537-547. （共同第一作者）

20. Hao Zheng, Sen Yang, Yuan Yang, Sheng-Xian Yuan,Fu-Quan Wu,Li-Li Wang, Hong-Li Yan, Shu-Han Sun, Wei-Ping Zhou. Epigenetically silenced long noncoding-SRHC promotes proliferation of hepatocellular carcinoma, J Cancer Res Clin Oncol (2014), DOI 10.1007/s00432-014-1871-4（IF 3.081） (共同通讯作者)

21. Yang S, Yan HL*, Tao QF, Yuan SX, Tang GN, Yang Y, Wang LL, Zhang YL, Sun SH, Zhou WP. Low CADM2 expression predicts high recurrence risk of hepatocellular carcinoma patients after hepatectomy. J Cancer Res Clin Oncol. 2014;140:109-116. （*Co-first author） (IF 3.009)

22. Yan H, Choi AJ, Lee BH, Ting AH. Identification and functional analysis of epigenetically silenced microRNAs in colorectal cancer cells. PLoS One. 2011; 6:e20628 1-11. （第一作者） (3.534)

23. Yan H, Xue G, Mei Q, Ding F, Sun SH. Calcium-dependent proapoptotic effect of Taenia solium metacestodes annexin B1 on human eosinophils: A novel strategy to prevent host immune response Int J Biochem Cell Biol. 2008;40:2151-63. （第一作者）（IF 4.956）

24. Hongli YAN, Liqiang HAO, Heiying JIN, Qinghe Xing, Geng XUE, Qian MEI, Jin HE, Lin HE, Shuhan SUN. Clinical features and mismatch repair genes analyses of Chinese suspected hereditary non-polyposis colorectal cancer: a cost-effective screening strategy proposal，Cancer Sci. 2008;99:770-80. （第一作者）(3.534)

25. Huang JJ, Yan HL*, Gao YJ, Sun SH, He Y, Ding FX, Mei Q, Xue G. Translocation of annexin B1 in response to the stimulation of PMA and ionomycin in cervical cancer cells. Cell Biol Int. 2008;32:121-7.（第一作者）（*Co-first author）

26. Yan H, Jin H, Xue G, Mei Q, Ding F, Hao L, Sun SH. Germline hMSH2 promoter mutation in a Chinese HNPCC kindred: evidence for dual role of LOH. Clin Genet. 2007;72:556-61 （第一作者）（IF 4.247）

27. Yan HL, Sun SH, Wang WT, Ding FX, Mei Q, Xue G. Design and characterization of a platelet-targeted plasminogen activator with enhanced thrombolytic and antithrombotic potency. Biotechnol Appl Bioc. 2007;46(Pt 2):115-25. （第一作者）

28. Gao YJ, Yan HL*, Ding FX, Lu YM, Sun SH. Annexin B1 at the host-parasite interface of the Taenia solium cysticercus: Secreted and associated with inflammatory reaction. Acta Trop. 2007;101:192-9 （第一作者）

29. Song LH, Yan HL*, Cai DL. Protective effects of soybean isoflavone against gamma-irradiation induced damages in mice. J Radiat Res (Tokyo). 2006;47:157-65.

30. Song LH, Yan HL*, Cai DL. Gene expression profiles in the liver of mice irradiated with (60)Co gamma rays and treated with soybean isoflavone. Eur J Nutr. 2006;45:406-17 （*Co-first author）

31. Ding FX, Yan HL*, Lu YM, Xue G, Mei Q, Huang JJ, Zhao ZY, Wang YZ, Sun SH. Cloning, purification and biochemical characterization of a thrombus-ditargeting thrombolytic agent, comprised of annexin B1, ScuPA-32K and fibrin-adherent peptide. J Biotechnol. 2006 ;126:394-405. （IF2.970）（*Co-first author）

32. Yan, HL; Wang, WT; He, Y, et al. Construction expression, and characterization of a recombinant annexin B1-low molecular weight urokinase chimera in Escherichia coli，Acta Biochimica et Biophysica Sinica, 2004, 36：184－190 （第一作者）

33. Yan, HL; Song, YL; Liu, F, et al. Homology modeling three-dimensional structure of AnxB1 and reducing its immunogenicity by sequence-de leted mutagenesis. SCIENCE IN CHINA SERIES C, 2004, 47: 359-367 （第一作者）

34. Hongli Y, Shuhan S, Ruiwen C, Yingjun G. Cloning and Functional Identification of a Novel Annexin Subfamily in Cysticercus cellulosae. MOL BIOCHEM PARASIT, 2002;197:1-5 （第一作者）

35. Xue G, Hao LQ, Ding FX, Mei Q, Huang JJ, Fu CG, Yan HL, Sun SH. Expression of annexin a5 is associated with higher tumor stage and poor prognosis in colorectal adenocarcinomas, J Clin Gastroenterol, 2009; 43:831-7. （共同通讯作者）

其他作者：

36. Ding FX, Yan HL, Mei Q, Xue G, Wang YZ, Gao YJ, Sun SH. A novel, cheap and effective fusion expression system for the production of recombinant proteins. Appl Microbiol Biot. 2007;77:483-8. 2010 ISI Impact factor: 3.280 18

37. Mei Q, Yan HL, Ding FX, Xue G, Huang JJ, Wang YZ, Sun SH. Single-nucleotide polymorphisms of mismatch repair genes in healthy Chinese individuals and sporadic colorectal cancer patients. Cancer Genet Cytogen. 2006;171:17-23 2010 ISI Impact factor: 1.551 25

38. Winter A, Yusof AM, Gao E, Yan HL, Sun SH, Hofmann A. Biochemical characterization of annexin B1 from Cysticercus cellulosae. FEBS J. 2006;273:3238-47. 2010 ISI Impact factor: 3.129 12

39. Wang F, He XW, Yan HL, Huang JJ, Zhang Y, Jiang L, Gao YJ, Sun SH. Non-fusion expression in Escherichia coli: Single-step purification of recombinant human annexin A5 for detection of apoptosis. Protein Expr Purif. 2006;45:80-7 2010 ISI Impact factor: 1.644 14

40. Zhang Y, Guo YJ, Sun SH, Yan HL, He Y. Non-fusion expression in Escherichia coli, purification, and characterization of a novel Ca2+- and phospholipid-binding protein annexin B1. Protein Expr Purif. 2004;34:68-74. 2010 ISI Impact factor: 1.644 25

41. Huang JJ, Wang Fang, Sun SH, Hongli Yan. The Activity of Cytosolic Phospholipase A2 is Inhibited by Annexin B1 annexins, 2005,2: 21-24 5

42. Yuan-Jian Gao, Yi Zhang, Hongli Yan, Yan H3, Fang Wang, Shuhan SUN, Separation and purification of recombinant annexin B1 by Ca2+-triggered precipitation, annexins, 2005,2: 18-20 3

43. Wang K, Guo Y, Li K, Lu Y, Zhang Y, Sun S, Yan H, Zhang S. Molecular characterization and anticoagulant activity of a novel annexin derived from the Taenia solium. Acta Trop. 2006;99:165-72 2010 ISI Impact factor: 2.262 5

44. Li X, Fang F, Song Y, Yan H, Chang H, Sun S, Chen Z. Essential sequence of influenza neuraminidase DNA to provide protection against lethal viral infection. DNA Cell Biol. 2006; 25:197-205. 2010 ISI Impact factor: 2.159 18

45. Zhang B, Yang Y, Shi X, Liao W, Chen M, Cheng AS, Yan H, Fang C, Zhang S, Xu G, Shen S, Huang S, Chen G, Lv Y, Ling T, Zhang X, Wang L, Zhuge Y, Zou X. Proton pump inhibitor pantoprazole abrogates adriamycin-resistant gastric cancer cell invasiveness via suppression of Akt/GSK-β/β-catenin signaling and epithelial-mesenchymal transition. Cancer Lett. 2015 Jan 28;356(2 Pt B):704-12. doi: 10.1016/j.can let.2014.10.016. Epub 2014 Oct 23. 5.621 7

46. Mei Q, Xue G, Li X, Wu Z, Li X, Yan H, Guo M, Sun S, Han W. Methylation-induced loss of miR-484 in microsatellite-unstable colorectal cancer promotes both viability and IL-8 production via CD137L. J Pathol. 2015 Jun;236(2):165-74

47. Tao K, Yang J, Hu Y, Sun Y, Tan Z, Duan J, Zhang F, Yan H, Deng A. Clinical significance of urothelial carcinoma associated 1 in colon cancer. Int J Clin Exp Med. 2015 Nov 15;8(11):21854-60. eCollection 2015

48. Duan C, Zhang B, Deng C, Cao Y, Zhou F, Wu L, Chen M, Shen S, Xu G, Zhang S, Duan G, Yan H, Zou X. Piperlongumine induces gastric cancer cell apoptosis and G2/M cell cycle arrest both in vitro and in vivo. Tumour Biol. 2016，Aug;37(8):10793-804. doi: 10.1007/s13277-016-4792-9